Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.
Also called NCT05164653
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT05164653
-
- Other papers using this trial's data
- Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor-neprilysin inhibition in acute heart failure: Insights from the PREMIER study
- In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial
- Uptitration of Sacubitril/Valsartan in Acute Heart Failure: Insight from the PREMIER Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Unknown status
Technical summary
Registry record NCT05164653. Randomized; no masking; primary purpose treatment. Start 2021-12-27 (actual); primary completion 2024-02-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)
- Condition
- Heart Failure
- Intervention (Drug)
- Sacubitril Valsartan Sodium Hydrate
- Intervention (Drug)
- Standard treatment
- Lead sponsor
- Saga University
Record details
- Record id
cardio:ct-nct05164653- Content hash
36256b1c886fb8162bfde7eff85238c697ebca4402018d1daed74f685dfdc360